Contributing Factors To Protein Catabolism In Acute Renal Failure

Impairment of metabolic functions by uremia toxins Endocrine factors Insulin resistance

Increased secretion of catabolic hormones (catecholamines, glucagon, glucocorticoids) Hyperparathyroidism

Suppression of release or resistance to growth factors Acidosis

Systemic inflammatory response syndrome (activation of cytokine network) Release of proteases

Inadequate supply of nutritional substrates Loss of nutritional substrates (renal replacement therapy)


Protein catabolism in acute renal failure (ARF): contributing factors. The causes of hypercatabolism in ARF are complex and multifold and present a combination of nonspecific mechanisms induced by the acute disease process and underlying illness and associated complications, specific effects induced by the acute loss of renal function, and, finally, the type and intensity of renal replacement therapy.

A major stimulus of muscle protein catabolism in ARF is insulin resistance. In muscle, the maximal rate of insulin-stimulated protein synthesis is depressed by ARF and protein degradation is increased even in the presence of insulin [9].

Acidosis was identified as an important factor in muscle protein breakdown. Metabolic acidosis activates the catabolism of protein and oxidation of amino acids independently of azotemia, and nitrogen balance can be improved by correcting the metabolic acidosis [13]. These findings were not uniformly confirmed for ARF in animal experiments [14].

Several additional catabolic factors are operative in ARF. The secretion of catabolic hormones (catecholamines, glucagon, glucocorticoids), hyperparathyroidism which is also present in ARF (see Fig. 18-22), suppression of or decreased sensitivity to growth factors, the release of proteases from activated leukocytes—all can stimulate protein breakdown. Moreover, the release of inflammatory mediators such as tumor necrosis factor and interleukins have been shown to mediate hypercatabolism in acute disease [1, 2].

The type and frequency of renal replacement therapy can also affect protein balance. Aggravation of protein catabolism, certainly, is mediated in part by the loss of nutritional substrates, but some findings suggest that, in addition, both activation of protein breakdown and inhibition of muscular protein synthesis are induced by hemodialysis [15].

Last (but not least), of major relevance for the clinical situation is the fact that inadequate nutrition contributes to the loss of lean body mass in ARF. In experimental animals, starvation potentiates the catabolic response of ARF [7].


Amino acid pools and amino acid utilization in acute renal failure (ARF). As a consequence of these metabolic alterations, imbalances in amino acid pools in plasma and in the intracellular compartment occur in ARF. A typical plasma amino acid pattern is seen [16]. Plasma concentrations of cysteine (CYS), taurine (TAU), methionine (MET), and phenylalanine (PHE) are elevated, whereas plasma levels of valine (VAL) and leucine (LEU) are decreased.

Moreover, elimination of amino acids from the intravascular space is altered. As expected from the stimulation of hepatic extraction of amino acids observed in animal experiments, overall amino acid clearance and clearance of most glucoplastic amino acids is enhanced. In contrast, clearances of PHE, proline (PRO), and, remarkably, VAL are decreased [16, 17]. ALA— alanine; ARG—arginine; ASN—asparagine; ASP—aspartate; CIT—citrulline; GLN—glutamine; GLU—glutamate; GLY— glycine; HIS—histidine; ORN—ornithine; PRO—proline; SER— serine; THR—threonine; TRP—tryptophan; TYR—tyrosine. (From Druml et al. [16]; with permission.)

FIGURE 18-10

Metabolic functions of the kidney and protein and amino acid metabolism in acute renal failure (ARF). Protein and amino acid metabolism in ARF are also affected by impairment of the metabolic functions of the kidney itself. Various amino acids are synthe-

sized or converted by the kidneys and released into the circulation: cysteine, methionine (from homocysteine), tyrosine, arginine, and serine [18]. Thus, loss of renal function can contribute to the altered amino acid pools in ARF and to the fact that several amino acids, such as arginine or tyrosine, which conventionally are termed nonessential, might become conditionally indispensable in ARF (see Fig. 18-11) [19].

In addition, the kidney is an important organ of protein degradation. Multiple peptides are filtered and catabolized at the tubular brush border, with the constituent amino acids being reabsorbed and recycled into the metabolic pool. In renal failure, catabolism of peptides such as peptide hormones is retarded. This is also true for acute uremia: insulin requirements decrease in diabetic patients who develop of ARF [20].

With the increased use of dipeptides in artificial nutrition as a source of amino acids (such as tyrosine and glutamine) which are not soluble or stable in aqueous solutions, this metabolic function of the kidney may also gain importance for utilization of these novel nutritional substrates. In the case of glycyl-tyrosine, metabolic clearance progressively decreases with falling creatinine clearance (open circles, 7 healthy subjects and a patient with unilateral nephrectomy*) but extrarenal clearance in the absence of renal function (black circles) is sufficient for rapid utilization of the dipeptide and release of tyrosine [21]. (From Druml et al. [21]; with permission.)

FIGURE 18-11

Amino acids in nutrition of acute renal failure (ARF): Conditionally essential amino acids. Because of the altered metabolic environment of uremic patients certain amino acids designated as nonessential for healthy subjects may become conditionally indispensable to ARF

patients: histidine, arginine, tyrosine, serine, cysteine [19]. Infusion of arginine-free amino acid solutions can cause life-threatening complications such as hyperammonemia, coma, and acidosis.

Healthy subjects readily form tyrosine from phenylalanine in the liver: During infusion of amino acid solutions containing phenylalanine, plasma tyrosine concentration rises (circles) [22]. In contrast, in patients with ARF (triangles) and chronic renal failure (CRF, squares) phenylalanine infusion does not increase plasma tyrosine, indicating inadequate interconversion.

Recently, it was suggested that glutamine, an amino acid that traditionally was designated non-essential exerts important metabolic functions in regulating nitrogen metabolism, supporting immune functions, and preserving the gastrointestinal barrier. Thus, it can become conditionally indispensable in catabolic illness [23]. Because free glutamine is not stable in aqueous solutions, dipeptides containing glutamine are used as a glutamine source in parenteral nutrition. The utilization of dipeptides in part depends on intact renal function, and renal failure can impair hydrolysis (see Fig. 18-10) [24]. No systematic studies have been published on the use of glutamine in patients with ARF, and it must be noted that glutamine supplementation increases nitrogen intake considerably.

Protein requirements

Urea nitrogen appearance (UNA) (g/d) = Urinary urea nitrogen (UUN) excretion + Change in urea nitrogen pool = (UUN X V) + (BUN2 - BUN1) 0.006 X BW + (BW2 - BW1) x BUN2/100

If there are substantial gastrointestinal losses, add urea nitrogen in secretions:

= volume of secretions X BUN2

Net protein breakdown (g/d) = UNA X 6.25

V is urine volume; BUN1 and BUN2 are BUN in mg/dL on days 1 and 2 BW1 and BW2 are body weights in kg on days 1 and 2


FIGURE 18-12

Estimation of protein catabolism and nitrogen balance. The extent of protein catabolism can be assessed by calculating the urea nitrogen appearance rate (UNA), because virtually all nitrogen arising from amino acids liberated during protein degradation is converted to urea. Besides urea in urine (UUN), nitrogen losses in other body fluids (eg, gastrointestinal, choledochal) must be added to any change in the urea pool. When the UNA rate is multiplied by 6.25, it can be converted to protein equivalents. With known nitrogen intake from the parenteral or enteral nutrition, nitrogen balance can be estimated from the UNA calculation.

Group Group Group

D^sof trjdtmirfc 71 65 85

¿minoKiddoH, 07 IS 174

^kgbw uhrsfldsfcü 1s£ 1&9 19.4 Ud hilrojiti 4j«r triors 1s.4 17.9 19.1

FIGURE 18-13

Amino acid and protein requirements of patients with acute renal failure (ARF). The optimal intake of protein or amino acids is affected more by the nature of the underlying cause of ARF and the extent of protein catabolism and type and frequency of dialysis than by kidney dysfunction per se. Unfortunately, only a few studies have attempted to define the optimal requirements for protein or amino acids in ARF:

In nonhypercatabolic patients, during the polyuric phase of ARF protein intake of 0.97 g/kg body weight per day was required to achieve a positive nitrogen balance [25]. A similar number (1.03g/kg body weight per day) was derived from a study in which, unfortunately, energy intake was not kept constant [6]. In the polyuric recovery phase in patients with sepsis-induced ARF, a nitrogen intake of 15 g/day (averaging an amino acid intake of 1.3 g/kg body weight per day) as compared to 4.4 g/kg per day (about 0.3 g/kg amino acids) was superior in ameliorating nitrogen balance [26].

Several recent studies have tried to evaluate protein and amino acid requirements of critically ill patients with ARF. Kierdorf and associates found that, in these hypercatabolic patients receiving continuous hemofiltration therapy, the provision of amino acids 1.5 g /kg body weight per day was more effective in reducing nitrogen loss than infusion of 0.7 g (-3.4 versus -8.1 g nitrogen per day) [27]. An increase of amino acid intake to 1. 74 g/kg per day did not further ameliorate nitrogen balance.

Chima and coworkers measured a mean PCR of 1.7 g kg body weight per day in 19 critically ill ARF patients and concluded that protein needs in these patients range between 1.4 and 1.7 g/kg per day [28]. Similarly, Marcias and coworkers have obtained a protein catabolic rate (PCR) of 1.4 g/kg per day and found an inverse relationship between protein and energy provision and PCR and again recommended protein intake of 1.5 to 1.8 g/kg per day [29]. Similar conclusions were drawn by Ikitzler in evaluating ARF patients on intermittent hemodialysis therapy [30]. (From Kierdorf et al. [27]; with permission.)

Glucose metabolism

FIGURE 18-14

Glucose metabolism in acute renal failure (ARF): Peripheral insulin resistance. ARF is commonly associated with hyperglycemia. The major cause of elevated blood glucose concentrations is insulin resistance [31]. Plasma insulin concentration is elevated. Maximal insulin-stimulated glucose uptake by skeletal muscle is decreased by 50 %, A, and muscular glycogen synthesis is impaired, B. However, insulin concentrations that cause half-maximal stimulation of glucose uptake are normal, pointing to a postreceptor defect rather than impaired insulin sensitivity as the cause of defective glucose metabolism. The factors contributing to insulin resistance are more or less identical to those involved in the stimulation of protein breakdown (see Fig. 18-8). Results from experimental animals suggest a common defect in protein and glucose metabolism: tyrosine release from muscle (as a measure of protein catabolism) is closely correlated with the ratio of lactate release to glucose uptake [9]. (From May et al. [31]; with permission.)

FIGURE 18-15

Glucose metabolism in acute renal failure (ARF): Stimulation of hepatic gluconeogenesis. A second feature of glucose metabolism (and at the same time the dominating mechanism of accelerated protein breakdown) in ARF is accelerated hepatic gluconeogenesis, mainly from conversion of amino acids released during protein catabolism. Hepatic extraction of amino acids, their conversion to glucose, and urea production are all increased in ARF (see Fig. 18-7) [12].

In healthy subjects, but also in patients with chronic renal failure, hepatic gluconeogenesis from amino acids is readily and completely suppressed by exogenous glucose infusion. In contrast, in ARF hepatic glucose formation can only be decreased, but not halted, by substrate supply. As can be seen from this experimental study, even during glucose infusion there is persistent gluconeogenesis from amino acids in acutely uremic dogs (•) as compared with controls dogs (o) whose livers switch from glucose release to glucose uptake [32].

These findings have important implications for nutrition support for patients with ARF: 1) It is impossible to achieve positive nitrogen balance; 2) Protein catabolism cannot be suppressed by providing conventional nutritional substrates alone. Thus, for future advances alternative means must be found to effectively suppress protein catab-olism and preserve lean body mass. (From Cianciaruso et al. [32]; with permission.)

Lipid metabolism

Renal Failure Degree
FIGURE 18-16

Lipid metabolism in acute renal failure (ARF). Profound alterations of lipid metabolism occur in patients with ARF. The triglyceride content of plasma lipoproteins, especially very low-density (VLDL) and low-density ones (LDL) is increased, while total cholesterol and in particular high-density lipoprotein (HDL) cholesterol are decreased [33,34]. The major cause of lipid abnormalities in ARF is impairment of lipolysis. The activities of both lipolytic systems, peripheral lipoprotein lipase and hepatic triglyceride lipase are decreased in patients with ARF to less than 50% of normal [35].

Maximal postheparin lipolytic activity (PHLA), hepatic triglyceride lipase (HTGL), and peripheral lipoprotein lipase (LPL) in 10 controls (open bars) and eight subjects with ARF (black bars). However, in contrast to this impairment of lipolysis, oxidation of fatty acids is not affected by ARF. During infusion of labeled long-chain fatty acids, carbon dioxide production from lipid was comparable between healthy subjects and patients with ARF [36]. FFA—free fatty acids. (Adapted from Druml et al. [35]; with permission.)

FIGURE 18-17

Impairment of lipolysis and elimination of artificial lipid emulsions in acute renal failure (ARF). Fat particles of artificial fat emulsions for parenteral nutrition are degraded as endogenous very low-density lipoprotein is. Thus, the nutritional consequence of the impaired lipolysis in ARF is delayed elimination of intravenously infused lipid emulsions [33, 34]. The increase in plasma triglycerides during infusion of a lipid emulsion is doubled in patients with ARF (N=7) as compared with healthy subjects (N=6). The clearance of fat emulsions is reduced by more than 50% in ARF. The impairment of lipolysis in ARF cannot be bypassed by using medium-chain triglycerides (MCT); the elimination of fat emulsions containing long chain triglycerides (LCT) or MCT is equally retarded in ARF [34]. Nevertheless, the oxydation of free fatty acid released from triglycerides is not inpaired in patients with ARF [36]. (From Druml et al. [34]; with permission.)

Electrolytes and micronutrients



Decreased renal elimination

Decreased renal elimination

Increased release during catabolism

Increased release from bone

2.38 mEq/g nitrogen

Increased release during catabolism:

0.36 mEq/g glycogen

2 mmol/g nitrogen

Decreased cellular uptake/

Decreased cellular uptake/utilization

increased release

and/or increased release from cells

Metabolic acidosis: 0.6 mmol/L rise/0.1

decrease in pH

Diabetes Sustenance

Diabetes Sustenance

Get All The Support And Guidance You Need To Be A Success At Dealing With Diabetes The Healthy Way. This Book Is One Of The Most Valuable Resources In The World When It Comes To Learning How Nutritional Supplements Can Control Sugar Levels.

Get My Free Ebook

Post a comment